A Phase 1B Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in Patients With BRAF-mutant Metastatic Melanoma (The CELEBRATE Study)
Latest Information Update: 09 Jan 2024
At a glance
- Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Palbociclib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms CELEBRATE
- 03 Jan 2024 Planned End Date changed from 4 Dec 2023 to 4 Dec 2024.
- 03 Jan 2024 Planned primary completion date changed from 4 Dec 2023 to 4 Dec 2024.
- 14 Mar 2023 Planned primary completion date changed from 4 Dec 2022 to 4 Dec 2023.